146 related articles for article (PubMed ID: 9732993)
41. [Tumor makrers in cervical cancer].
Markowska J
Ginekol Pol; 2007 Sep; 78(9):715-8. PubMed ID: 18159826
[TBL] [Abstract][Full Text] [Related]
42. Disruption of the circadian patterns of serum cortisol in breast and ovarian cancer patients: relationships with tumour marker antigens.
Touitou Y; Bogdan A; Lévi F; Benavides M; Auzéby A
Br J Cancer; 1996 Oct; 74(8):1248-52. PubMed ID: 8883412
[TBL] [Abstract][Full Text] [Related]
43. [Clinical Significance of Tumor Marker Detection in Patients
with Advanced Squamous Cell Carcimoma of the Lung].
Liang P; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):641-647. PubMed ID: 27760591
[TBL] [Abstract][Full Text] [Related]
44. Multiple tumour marker assays in advanced cervical cancer: relationship to chemotherapy response and clinical outcome.
Scambia G; Benedetti Panici ; Foti E; Ferrandina G; Leone FP; Marciano M; Mancuso S
Eur J Cancer; 1996 Feb; 32A(2):259-63. PubMed ID: 8664038
[TBL] [Abstract][Full Text] [Related]
45. Peri- and postoperative changes in serum levels of four tumor markers and three acute phase reactants in benign and malignant gynecological diseases.
Avall-Lundqvist E; Sjövall K; Hansson LO; Eneroth P
Arch Gynecol Obstet; 1992; 251(2):69-78. PubMed ID: 1374604
[TBL] [Abstract][Full Text] [Related]
46. Prognostic significance of tumour markers in endometrial cancer.
Lo SS; Cheng DK; Ng TY; Wong LC; Ngan HY
Tumour Biol; 1997; 18(4):241-9. PubMed ID: 9218009
[TBL] [Abstract][Full Text] [Related]
47. Interchangeability between control material and patient serum in tumor biomarker assessment.
Dittadi R; Gion M
Int J Biol Markers; 2003; 18(3):230-1. PubMed ID: 14535596
[No Abstract] [Full Text] [Related]
48. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
[TBL] [Abstract][Full Text] [Related]
49. Clinical evaluation of mature teratomas containing malignant elements.
Hirai K; Ishiko O; Itoh F; Nakagawa E; Kanaoka Y; Sumi T; Ogita S
Oncol Rep; 2000; 7(3):655-7. PubMed ID: 10767385
[TBL] [Abstract][Full Text] [Related]
50. Clinical applications of serum markers for lung cancer.
Ferrigno D; Buccheri G
Respir Med; 1995 Oct; 89(9):587-97. PubMed ID: 7494910
[No Abstract] [Full Text] [Related]
51. Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible?
Yang Q; Zhang P; Wu R; Lu K; Zhou H
Dis Markers; 2018; 2018():2082840. PubMed ID: 30364165
[TBL] [Abstract][Full Text] [Related]
52. Elevated CA125 in breast cancer--A sign of advanced disease.
Norum LF; Erikstein B; Nustad K
Tumour Biol; 2001; 22(4):223-8. PubMed ID: 11399947
[TBL] [Abstract][Full Text] [Related]
53. Detection of serum p53 antibodies in patients with esophageal squamous cell carcinoma: correlation with clinicopathologic features and tumor markers.
Shimada H; Nakajima K; Ochiai T; Koide Y; Okazumi SI; Matsubara H; Takeda A; Miyazawa Y; Arima M; Isono K
Oncol Rep; 1998; 5(4):871-4. PubMed ID: 9625835
[TBL] [Abstract][Full Text] [Related]
54. Reference limits for chromogranin A, CYFRA 21-1, CA 125, CA 19-9 and carcinoembryonic antigen in patients with chronic kidney disease.
Mikkelsen G; Åsberg A; Hultström ME; Aasarød K; Hov GG
Int J Biol Markers; 2017 Oct; 32(4):e461-e466. PubMed ID: 28561881
[TBL] [Abstract][Full Text] [Related]
55. Squamous cell carcinoma antigen and cancer antigen 125 in southern Indian cervical cancer patients.
Porika M; Vemunoori AK; Tippani R; Mohammad A; Bollam SR; Abbagani S
Asian Pac J Cancer Prev; 2010; 11(6):1745-7. PubMed ID: 21338226
[TBL] [Abstract][Full Text] [Related]
56. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values.
Bon GG; Kenemans P; Verstraeten R; van Kamp GJ; Hilgers J
Am J Obstet Gynecol; 1996 Jan; 174(1 Pt 1):107-14. PubMed ID: 8571992
[TBL] [Abstract][Full Text] [Related]
57. A system for tumor heterogeneity evaluation and diagnosis based on tumor markers measured routinely in the laboratory.
Hui L; Rixv L; Xiuying Z
Clin Biochem; 2015 Dec; 48(18):1241-5. PubMed ID: 26216289
[TBL] [Abstract][Full Text] [Related]
58. Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies.
Solakidi S; Dessypris A; Stathopoulos GP; Androulakis G; Sekeris CE
Clin Biochem; 2004 Jan; 37(1):56-60. PubMed ID: 14675563
[TBL] [Abstract][Full Text] [Related]
59. Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer.
Hermann N; Dressen K; Schroeder L; Debald M; Schildberg FA; Walgenbach-Bruenagel G; Hettwer K; Uhlig S; Kuhn W; Hartmann G; Holdenrieder S
Tumour Biol; 2017 Jun; 39(6):1010428317711381. PubMed ID: 28618926
[TBL] [Abstract][Full Text] [Related]
60. The efficacy of serum carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3), alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG) levels in determining the malignancy of solitary pulmonary nodules.
Bekci TT; Senol T; Maden E
J Int Med Res; 2009; 37(2):438-45. PubMed ID: 19383238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
